XM does not provide services to residents of the United States of America.
B
B

Biomerieux


News

Berenberg upgrades Biomerieux on growth potential

BUZZ-Berenberg upgrades Biomerieux on growth potential ** Berenberg upgrades Biomerieux BIOX.PA to "buy" from "hold" as it expects new product launches to drive growth for the French diagnostics company ** It points to a "remarkably strong" Q4 performance of Biomerieux's new product in molecular infectious disease diagnostics, SPOTFIRE ** The broke
B

Biomerieux, Pernod Ricard, Remy Cointreau

EUROPE RESEARCH ROUNDUP-Biomerieux, Pernod Ricard, Remy Cointreau March 21 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Biomerieux, Pernod Ricard and Remy Cointreau, on Thursday. HIGHLIGHTS * Biomerieux SA BIOX.PA : Berenberg raises to buy from hold * Diasorin SpA DIAS.MI : Berenberg cuts to hold from buy * Pernod Ricard PERP.PA : Deutsche Bank raises to hold from sell * Remy Cointreau RCOP.PA : Deutsche Bank raises to buy from
A
A
B
B
C
C
C
C
C
D
E
H
H
I
I
R
R
S
A
A
B
D
P
S

Aston Martin, Bodycote, Systemair

EUROPE RESEARCH ROUNDUP- Aston Martin, Bodycote, Systemair March 18 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Aston Martin, Bodycote, and Systemair, on Monday. HIGHLIGHTS * Aston Martin AML.L : Jefferies cuts target price to 275p from 330p * Bodycote Plc BOY.L : JP Morgan raises target price to 620p from 600p * Novo Nordisk NOVOb.CO : Berenberg raises target price to DKK 900 from DKK 850 * Systemair AB SYSR.ST : Jefferies rais
A
A
A
A
A
B
B
B
B
C
C
C
C
D
E
E
E
G
H
I
L
L
P
P
S
A
A
A
A
D
P
U

Believe, Deliveroo, Mondi

EUROPE RESEARCH ROUNDUP-Believe, Deliveroo, Mondi March 15 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Believe, Deliveroo and Mondi, on Friday. HIGHLIGHTS * Believe BLV.PA : HSBC cuts to hold from buy * CVS Group Plc CVSG.L : RBC cuts to sector perform from outperform * Deliveroo Plc ROO.L : HSBC raises to buy from hold * Encavis AG ECVG.DE : Morgan Stanley raises to equal weight from underweight * Mondi MNDI.L : Jefferies raise
A
A
B
B
C
C
C
D
E
E
G
G
G
H
I
I
I
K
L
M
M
O
P
R
R
S
T
V
W
Z
D
S

Believe SA, Inditex, Legal & General Group

EUROPE RESEARCH ROUNDUP-Believe SA, Inditex, Legal & General Group March 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Believe SA, Inditex and Legal & General Group, on Thursday. HIGHLIGHTS * Believe SA BLV.PA : JP Morgan raises target price to EUR 15 from EUR 11.6 * Inditex ITX.MC : JP Morgan raises target price to EUR 48 from EUR 42 * Kardex Holding AG KARN.S : Jefferies cuts to hold from buy * Legal & General Group Plc LGEN.
A
A
A
B
B
B
C
C
E
E
F
F
G
I
L
L
L
L
P
P
R
S
Z
A
P
S
Y

Biomerieux Sees 2024 Sales Growth Of Between +6% And +8%

BRIEF-Biomerieux Sees 2024 Sales Growth Of Between +6% And +8% March 14 (Reuters) - Biomerieux SA BIOX.PA : Q4 2023 TOTAL SALES OF EUR 1 BILLION, UP 3.1% ORGANIC ON A HIGH TRIPLE DEMIC COMPARISON BASIS IN Q4 2022 FY CONTRIBUTIVE OPERATING INCOME REACHED €610 MILLION (16.6% OF SALES), UP 2% AT CONSTANT EXCHANGE RATE AND SCOPE OUTLOOK 2024: CONTRIBUTIVE OPERATING INCOME BEFORE NON-RECURRING ITEMS IS EXPECTED TO GROW AT LEAST BY +10% AT CONSTANT EXCHANGE RATES 2024 GUIDANCE: SALES GROWTH BETWEEN
B

Europe's STOXX 600 corporate earnings week ahead

DIARY-Europe's STOXX 600 corporate earnings week ahead March 8 (Reuters) - Diary of Europe's STOXX 600 (.STOXX) corporate earnings for the week ahead EUROPE'S STOXX 600 EARNINGS Start Date Start Time (GMT) RIC Company Name Event Name 11-Mar-2024 NTS HRA.MI Hera SpA Q4 2023 Hera SpA Earnings Release 11-Mar-2024 NTS LEGn.DE LEG Immobilien SE Q4 2023 LEG Immobilien SE Earnings Release 11-Mar-2024 NTS LDOF.MI Leonardo SpA Full Year 2023 Leonardo SpA Earnings Release 12-Mar-2024 NTS BKWB.S BKW AG Ful
A
B
B
B
D
E
G
I
K
L
L
L
P
R
R
S
V
V
W
Z
A
D
S

Biomerieux Appoints Dr. Charles  K. Cooper As Chief Medical Officer

BRIEF-Biomerieux Appoints Dr. Charles  K. Cooper As Chief Medical Officer Jan 16 (Reuters) - Biomerieux SA BIOX.PA : APPOINTS DR. CHARLES K. COOPER AS EXECUTIVE VICE PRESIDENT, CHIEF MEDICAL OFFICER, EFFECTIVE JANUARY 2ND, 2024 APPOINTS CÉLINE ROGER-DALBERT AS EXECUTIVE VICE PRESIDENT RESEARCH AND DEVELOPMENT, EFFECTIVE MARCH 1ST, 2024 Sou
B

EPS to determine 2024 winners and losers in European medtech -MS

BUZZ-EPS to determine 2024 winners and losers in European medtech -MS ** Morgan Stanley expects earnings per share (EPS) to indicate 2024 winners and losers in European medical technology, saying EPS revisions should produce above-average price moves after some recovery in 2023 ** It notes 2023 already saw some earnings re-basing due to a combinati
B
S
A
F

Biomerieux Acquires LUMED

BRIEF-Biomerieux Acquires LUMED Jan 8 (Reuters) - Biomerieux SA BIOX.PA : BIOMERIEUX ACQUIRES LUMED TO REINFORCE ITS SOFTWARE PORTFOLIO IN FIGHT AGAINST ANTIMICROBIAL RESISTANCE ACQUIRED THE ENTIRE SHARE CAPITAL OF CANADIAN INNOVATIVE SOFTWARE COMPANY LUMED, INCREASING ITS STAKE FROM 16% TO 100% ACQUISITION OF 84% OF THE CAPITAL REPRESENTS AN INVES
B

Admiral Group, Endesa, Wizz Air

EUROPE RESEARCH ROUNDUP-Admiral Group, Endesa, Wizz Air Jan 8 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Admiral Group, Endesa, and Wizz Air, on Monday. HIGHLIGHTS * Admiral Group Plc ADML.L : HSBC raises target price to 2500p from 2200p * Boliden AB BOL.ST : Bernstein cuts to market-perform from outperform * CMC Markets Plc CMCX.L : Peel Hunt raises to buy from add * Endesa ELE.MC : Goldman Sachs raises to buy from neutral * W
A
A
A
B
B
B
B
B
B
B
B
C
C
C
C
C
D
E
E
E
F
F
H
J
L
N
P
R
R
S
S
A
A
A
A
D
D
D
E
F
R
T

Argenx, Epiroc, Volkswagen

EUROPE RESEARCH ROUNDUP- Argenx, Epiroc, Volkswagen Nov 1 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Argenx, Epiroc and Volkswagen, on Wednesday. HIGHLIGHTS * Argenx SE ARGX.BR : JP Morgan raises target price to EUR 580 from EUR 560 * Epiroc AB EPIRa.ST : RBC cuts target price to SEK 195 from SEK 205 * Hipgnosis Songs Fund Ltd SONG.L : JP Morgan resumes coverage with overweight rating * Safran SAF.PA : Berenberg raises target
B
B
C
D
I
N
P
S
S
S
S
V
W
B

Biomerieux Confirmation Of The 2023 Guidance

BRIEF-Biomerieux Confirmation Of The 2023 Guidance Oct 26 (Reuters) - Biomerieux SA BIOX.PA : BIOMÉRIEUX – THIRD-QUARTER 2023 BUSINESS REVIEW +8.0% SALES ORGANIC GROWTH OVER THE FIRST NINE MONTHS OF THE YEAR Q3 SALES ORGANIC GROWTH AT +7.1% (+10.3% EXCLUDING BIOFIRE® RESPIRATORY PANELS), ON PAR WITH EXPECTATIONS CONFIRMATION OF THE 2023 GUIDANC
B

Is the worst over for medical equipment companies?

LIVE MARKETS-Is the worst over for medical equipment companies? STOXX Europe 600 down 0.85% Treasuries graze 5% Middle East conflict weighs Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com IS THE WORST OVER FOR MEDICAL EQUIPMENT COMPANIES?
B
I
N
N
N
S
Q
D
E
F
U
G

UK Stocks-Factors to watch on Oct 19

UPDATE 1-UK Stocks-Factors to watch on Oct 19 Adds news items, updates futures Oct 19 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Thursday, with futures FFIc1 down 0.56%. * LSEG: London Stock Exchange Group is on track to end the year towards the upper end of its income growth targets, having established a "consistent track record" in data and analytics, it said.
B
H
M
M
R
R
S

France's bioMérieux to invest 70 mln stg in Oxford Nanopore

France's bioMérieux to invest 70 mln stg in Oxford Nanopore Oct 19 (Reuters) - France's bioMérieux BIOX.PA will invest 70 million pounds ($85 million) in Britain's Oxford Nanopore Technologies ONT.L , the companies said in a joint statement on Thursday. The medical diagnostic technology firm also expects to make further purchases up to 3.5% of Oxford Nanopore stock, they said.
B

Biomerieux Makes Strategic Investment In Oxford Nanopore

BRIEF-Biomerieux Makes Strategic Investment In Oxford Nanopore Oct 19 (Reuters) - Biomerieux SA BIOX.PA : BIOMÉRIEUX TO SUBSCRIBE FOR 29,025,326 ORDINARY SHARES IN OXFORD NANOPORE AT A SUBSCRIPTION PRICE OF 238.08P PER SHARE MAKES STRATEGIC INVESTMENT IN OXFORD NANOPORE ANNOUNCE THAT BIOMÉRIEUX IS MAKING AN IMMEDIATE £70M INVESTMENT IN OXFORD NA
B

Biomerieux Receives Marking Of VIDAS TBI

BRIEF-Biomerieux Receives CE-Marking Of VIDAS TBI Oct 13 (Reuters) - Biomerieux SA BIOX.PA : CE-MARKING OF VIDAS® TBI (GFAP, UCH-L1), A TEST FOR IMPROVED ASSESSMENT OF PATIENTS WITH MILD TRAUMATIC BRAIN INJURY, INCLUDING CONCUSSION Source text for Eikon: https://tinyurl.com/bd7ju3um Further company coverage: BIOX.PA (Gdansk Newsroom)
B

Colonial, Croda, IHG

EUROPE RESEARCH ROUNDUP-Colonial, Croda, IHG Oct 11 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Colonial, Croda and IHG on Wednesday. HIGHLIGHTS * A.P. Moller-Maersk MAERSKb.CO : Deutsche Bank cuts to sell from hold * Colonial COL.MC : Goldman Sachs cuts to neutral from buy * Croda CRDA.L : JP Morgan raises to neutral from underweight * Delivery Hero SE DHER.DE : Exane BNP Paribas raises to neutral from underperform * IHG IHG.L
A
B
B
B
C
C
E
G
I
L
M
M
N
R
R
S
A
A
B
D

U.S. STOCKS Mercato, Baytex, Ball Corp

BUZZ-U.S. STOCKS ON THE MOVE-Mercato, Baytex, Ball Corp Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The S&P 500 and the Nasdaq rose on Friday after a softer-than-expected reading on a crucial inflation metric kept alive hopes of a pause in the Federal Reserve's rate hikes, though all three main Wall Street indexes were on track for quarterly declines.
B
C
C
I
J
N
O
W
Q
U
U



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.